Skip to main content

Table 1 Baseline patient and tumor characteristics stratified by circulating tumor cell count

From: Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination

Variable Overall,N(%) CTCs <5/7.5 ml,n(%) CTCs ≥5/7.5 ml,n(%) P-value
Overall population 492 (100) 303 (61.6) 189 (38.4) -
Treatment strategy     
Systemic treatment only 467 (94.9) 286 (94.7) 180 (95.2) ns
Additional locoregional treatment 25 (5.1)a 16 (5.3) 9 (4.8)
Line of treatment     
First 232 (47.2) 139 (45.9) 93 (49.2) ns
Second or later 260 (52.8) 164 (54.1) 96 (50.8)
Type of systemic treatment     
Chemotherapy 376 (76.4) 218 (71.9) 158 (83.6) 0.0041
Endocrine therapy 103 (20.9) 73 (24.1) 30 (15.9)
Other 13 (2.7) 12 (4.0) 1 (0.5)
Number of metastatic sites     
1 146 (29.7) 104 (34.3) 42 (22.2) 0.0077
2 145 (29.5) 89 (29.4) 56 (29.6)
≥3 201 (40.8) 110 (36.3) 91 (48.2)
Distribution of metastatic sites     
Lymph nodes/soft tissuesb 58 (11.8) 48 (15.8) 10 (5.3) 0.0003
Bonec 326 (66.2) 172 (56.8) 154 (81.5) <0.0001
Viscerad 306 (62.2) 184 (60.7) 122 (64.6) ns
Braine 37 (7.5) 23 (7.6) 14 (7.4) ns
  1. aAdditional locoregional treatments: surgery 15 (3.0%); radiation therapy 8 (1.6%); other 2 (0.4%). bLymph nodes/soft tissue only. cBone with or without other sites. dVisceral organs (including brain) with or without other sites. eBrain with or without other sites. CTCs, Circulating tumor cells; ns, Statistically nonsignificant.